SK Biopharm Reports 63 Billion KRW Operating Loss in Q3... Deficit Widens

[Asia Economy Reporter Eunmo Koo] SK Biopharm announced on the 12th that its operating loss based on consolidated financial statements for the third quarter of this year was tentatively estimated at 63.036 billion KRW, representing a 24.8% increase in the deficit compared to the same period last year. During the same period, sales increased by 4704% to 3.923 billion KRW, and net loss for the period expanded by 25.5% to 63.074 billion KRW.

This content was produced with the assistance of AI translation services.